G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational,
multicenter prospective observational cohort registry, with the goal of collecting
clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk
factors associated with increased incidence of cancer therapy related cardiovascular
toxicity (CTR-CVT) in different settings and to derive and validate risk scores for
cardio oncology patients treated in different geographic locations throughout the world.
G-COR will involve the collaboration from 124 hospitals from 24 countries that completed
survey with sites demographics. It will evaluate cardiovascular disease in three distinct
populations of cancer patients (hematological malignancies: lymphomas, leukemias,
multiple myeloma; breast cancer patients; and patients treated with check point
inhibitors immunotherapy).
G-COR will evaluate the cardiovascular impact of different cancer treatments in the
above-described patients, and similarities and differences in diagnostic and treatment
modalities as well as outcomes and the impact of socioeconomic factors and risk factors
for toxicities in a large worldwide population.
G-COR will study the impact of cancer in CV disease in cancer patients treated at
academic centers as well as in patients treated at community hospitals, through a
systematic prospective data collection in a global digital platform.
G-COR is an IRB approved prospective registry, conducted with the logistical support of
C5 Clinical Research Division and the Cardiovascular Outcomes Registries and Research
(CORR) group at the Cleveland Clinic and have developed eCRFs with an extensive Red Cap
Cloud platform.
G-COR Executive, Scientific and topic committees are led by North American, European,
Latin American, Australian and Asian representatives from both academic and community
centers.
G-COR Pilot US, was completed (phase 1) with breast cancer patients from 18 US Centers
and enrolled 700 patients.
G-COR Global Phase 2, has now started enrolling patients from the three pillars (-breast
cancer, -hematological malignancies, and -patients treated with immune check point
inhibitors (ICI). Enrollment of phase 2 started in early 2026 and will continue with
enrollment and follow up until July 2029.
G-COR Global International will start in 2026 with centers from Europe, Latin America,
Australia, Asia and Africa.
